Chronic Graft-Versus-Host Disease Clinical Trial
Official title:
A Phase II Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
There is a clear need for effective, steroid-sparing agents for the management of chronic
graft-versus-host disease (GVHD). Thus, agents like Histone deacetylase (HDAC) inhibitors,
with the potential of decreasing pro-inflammatory events leading to GVHD without affecting
graft-versus-leukemia (GVL), may have a central role in the prevention and treatment of
GVHD.
This study will look at the efficacy of panobinostat (LBH589), an HDAC inhibitor, in the
treatment of patients with chronic GVHD who have failed corticosteroids. In this group of
patients, effective steroid-sparing options are limited and are usually associated with
profound immunosuppression and decreased GVL effect.
Chronic GVHD is an autoimmune, inflammatory disorder that occurs in the majority of patients
who experience acute GVHD. Long-term corticosteroids are still standard therapy for chronic
GVHD. Corticosteroids are associated with high morbidity and non-relapse mortality. In
addition, corticosteroids are broadly immunosuppressive and can also decrease the GVL effect
and increase the incidence of relapse. There is a clear need for effective, steroid-sparing
agents for the management of chronic GVHD. Thus, agents like HDAC inhibitors, with the
potential of decreasing pro-inflammatory events leading to GVHD without affecting GVL, may
have a central role in the prevention and treatment of GVHD.
This study will look at the efficacy of panobinostat (LBH589), an HDAC inhibitor, in the
treatment of patients with chronic GVHD who have failed corticosteroids. In this group of
patients, effective steroid-sparing options are limited and are usually associated with
profound immunosuppression and decreased GVL effect.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02991846 -
A Prospective Observational Study for Evaluating CGVHD
|
||
| Recruiting |
NCT02291770 -
Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
|
Phase 3 | |
| Terminated |
NCT01226420 -
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
|
Phase 2 | |
| Active, not recruiting |
NCT02759731 -
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT01862965 -
Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
|
Phase 2 | |
| Completed |
NCT02411474 -
Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD
|
N/A | |
| Completed |
NCT02040623 -
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
|
Phase 2 | |
| Active, not recruiting |
NCT01158105 -
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
|
Phase 2 | |
| Terminated |
NCT01903473 -
Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
|
Phase 2 | |
| Active, not recruiting |
NCT01366092 -
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
|
Phase 2 | |
| Not yet recruiting |
NCT06458127 -
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
|
N/A | |
| Recruiting |
NCT05690971 -
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
|
N/A | |
| Recruiting |
NCT02918188 -
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
|
Phase 2 | |
| Recruiting |
NCT01765660 -
Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease
|
Phase 2 | |
| Completed |
NCT01956903 -
Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.
|
Phase 1/Phase 2 | |
| Terminated |
NCT03584516 -
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04692376 -
MSC for Treatment of cGVHD After Allo-HSCT
|
Phase 2 | |
| Completed |
NCT02966301 -
Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
|
Phase 2 | |
| Terminated |
NCT01898377 -
Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children
|
Phase 2 | |
| Recruiting |
NCT02611180 -
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
|